Sector
PharmaceuticalsCMP
as on 03 Jul, 2024 12:00:00 AM
Open
₹213Prev. Close
₹209.98Turnover(Lac.)
₹111.45Day's High
₹213Day's Low
₹205.352 Week's High
₹263.8552 Week's Low
₹132.61Book Value
₹29.11Face Value
₹1Mkt Cap (₹ Cr.)
1,898.05P/E
76.47EPS
2.69Divi. Yield
0.246 Jun 2024
12:00 AM
Board Meeting
Agenda : Audited Result
13 May 2023
12:00 AM
Dividend
Dividend Amount: 5
13 May 2023
12:00 AM
AGM
Announcement Date: 13 May, 2023
13 May 2023
12:00 AM
Split
13 May 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 9.2 | 9.2 | 9.19 | 9.19 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 272.62 | 234.28 | 176.61 | 150.13 |
Net Worth | 281.82 | 243.48 | 185.8 | 159.32 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 230.66 | 201.58 | 209.5 | 216.65 |
yoy growth (%) | 14.42 | -3.77 | -3.3 | 6.78 |
Raw materials | -78.2 | -63.18 | -71.66 | -70.7 |
As % of sales | 33.9 | 31.34 | 34.2 | 32.63 |
Employee costs | -39.98 | -44.27 | -44.61 | -39.99 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 32.24 | 18 | 9.39 | 16.39 |
Depreciation | -8.54 | -8.26 | -7.4 | -7.47 |
Tax paid | -5.62 | -2.09 | -0.1 | -1.6 |
Working capital | 7.89 | 27.14 | 18.07 | 18.93 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.42 | -3.77 | -3.3 | 6.78 |
Op profit growth | 39.8 | 39.17 | -21.85 | 4.4 |
EBIT growth | 45.57 | 45.24 | -24.69 | 5.8 |
Net profit growth | 67.29 | 71.19 | -37.16 | -1.8 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 381.76 | 354.32 | 394.61 | 230.67 | 201.59 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 381.76 | 354.32 | 394.61 | 230.67 | 201.59 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 23.56 | 25.12 | 17.88 | 13.1 | 12.37 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,523.8 | 120.29 | 3,65,682.64 | 867.6 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,560.6 | 76.97 | 1,21,312.5 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,482.95 | 32.36 | 1,20,195.02 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,089.65 | 31.35 | 1,08,114.81 | 1,405.2 | 0.28 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,482.35 | 24.48 | 1,06,298.05 | 1,034.8 | 0.63 | 5,081.8 | 1,453.02 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec & Non-Independent Dir
Rajneesh Anand
Independent Non Exe. Director
Hari Subramaniam
Managing Director & CEO
Sachin D Patel
Executive Chairman
Dinesh S Patel
Independent Non Exe. Director
Manjul Sandhu
Independent Non Exe. Director
Bhaskar Vemban Iyer
Independent Non Exe. Director
Shishir Dalal
Alternate Director
Reena S Patel
Non-Exec. & Independent Dir.
Nikunt Raval
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Themis Medicare Ltd
Summary
Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.In Mar.95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments.Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary.The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products thro
Read More
What is the Themis Medicare Ltd share price today?
The Themis Medicare Ltd shares price on nse is Rs.₹206.22 today.
What is the Market Cap of Themis Medicare Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Themis Medicare Ltd is ₹1898.05 Cr. as of 03 Jul ‘24
What is the PE and PB ratio of Themis Medicare Ltd?
The PE and PB ratios of Themis Medicare Ltd is 76.47 and 7.07 as of 03 Jul ‘24
What is the 52 Week High and Low of Themis Medicare Ltd?
The 52-week high/low is the highest and lowest price at which a Themis Medicare Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Themis Medicare Ltd is ₹132.61 and ₹263.85 as of 03 Jul ‘24
What is the CAGR of Themis Medicare Ltd?
Themis Medicare Ltd's CAGR for 5 Years at 59.28%, 3 Years at 46.39%, 1 Year at 56.68%, 6 Month at -3.63%, 3 Month at -6.82% and 1 Month at -0.01%.
What is the shareholding pattern of Themis Medicare Ltd?
The shareholding pattern of Themis Medicare Ltd is as follows:
Promoters - 67.15 %
Institutions - 0.04 %
Public - 32.81 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
